UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer

The New England journal of medicine, 2019-03, Vol.380 (13), p.1235-1246

2019

Volltextzugriff (PDF)

Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide

The New England journal of medicine, 2020-09, Vol.383 (11), p.1040-1049

2020

Volltextzugriff (PDF)

First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours

British journal of cancer, 2020-12, Vol.123 (12), p.1730-1736

2020

Volltextzugriff (PDF)

Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial

International journal of clinical oncology, 2021-03, Vol.26 (3), p.578-590

2021

Volltextzugriff (PDF)

Effects of low and high plasma concentrations of dexmedetomidine on myocardial perfusion and cardiac function in healthy male subjects

Anesthesiology (Philadelphia), 2006-11, Vol.105 (5), p.902-910

2006

Volltextzugriff (PDF)

Prospective-–retrospective biomarker analysis for regulatory consideration: white paper from the industry pharmacogenomics working group

Pharmacogenomics, 2011-07, Vol.12 (7), p.939-951

2011

Volltextzugriff (PDF)

Effects of common polymorphisms in the α1A-, α2B-, β1- and β2-adrenoreceptors on haemodynamic responses to adrenaline

Clinical science (1979), 2003-05, Vol.104 (5), p.509-520

2003

Volltextzugriff (PDF)

Prediction and impact of attacks of Raynaud's phenomenon, as judged by patient perception

Rheumatology (Oxford, England), 2015-08, Vol.54 (8), p.1443-1447

2015

Volltextzugriff (PDF)

An insertion/deletion polymorphism in the α2b-adrenergic receptor gene is a novel genetic risk factor for acute coronary events

Journal of the American College of Cardiology, 2001-05, Vol.37 (6), p.1516-1522

2001

Volltextzugriff (PDF)

Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial

European journal of cancer (1990), 2021-09, Vol.154, p.138-146

2021

Volltextzugriff (PDF)

Acoustic cluster therapy: An overview of research in cancer treatment

The Journal of the Acoustical Society of America, 2024-03, Vol.155 (3_Supplement), p.A287-A287

2024

Volltextzugriff (PDF)

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer

The New England journal of medicine, 2022-09, Vol.387 (9), p.860-860

2022

Volltextzugriff (PDF)

Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: An Open-label Phase 1 Study

European urology, 2016-05, Vol.69 (5), p.834-840

2016

Volltextzugriff (PDF)

Abstract 6221: First-in-human study of acoustic cluster therapy consisting of PS101 combined with chemotherapy and insonation in patients with liver metastases of colorectal cancer origin

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.6221-6221

2024

Volltextzugriff (PDF)

Impact of darolutamide (DARO) on pain and quality of life (QoL) in patients (Pts) with nonmetastatic castrate-resistant prostate cancer (nmCRPC)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.5000-5000

2019

Volltextzugriff (PDF)

Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.5514-5514

2020

Volltextzugriff (PDF)

The Effects of Sympathectomy on Finger Photoplethysmography and Temperature Measurements in Healthy Subjects

Anesthesia and analgesia, 2011-07, Vol.113 (1), p.78-83

2011

Volltextzugriff (PDF)

LBA-09 DAROLUTAMIDE DELAYS PROSTATE-SPECIFIC ANTIGEN PROGRESSION AND TIME TO NEXT ANTICANCER THERAPIES IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER

The Journal of urology, 2019-04, Vol.201 (Supplement 4)

2019

Volltextzugriff (PDF)

ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC)

Journal of clinical oncology, 2019-03, Vol.37 (7_suppl), p.140-140

2019

Volltextzugriff (PDF)

ARAMIS trial: Efficacy and safety of ODM-201 in men with high-risk nonmetastatic castration-resistant prostate cancer

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.TPS5094-TPS5094

2016

Volltextzugriff (PDF)

ARAMIS trial: Efficacy and safety phase 3 trial of ODM-201 in men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.TPS5080-TPS5080

2015

Volltextzugriff (PDF)

A double-blind, randomized, placebo-controlled crossover trial of the α2C-adrenoceptor antagonist ORM-12741 for prevention of cold-induced vasospasm in patients with systemic sclerosis

Rheumatology (Oxford, England), 2014-05, Vol.53 (5), p.948

2014

Volltextzugriff (PDF)

ODM-201 and the CNS: A clinical perspective

Journal of clinical oncology, 2014-02, Vol.32 (4_suppl), p.275-275

2014

Volltextzugriff (PDF)

Variation in the alpha2B-adrenoceptor gene as a risk factor for prehospital fatal myocardial infarction and sudden cardiac death

Journal of the American College of Cardiology, 2003-01, Vol.41 (2), p.190-194

2003

Volltextzugriff (PDF)

A study of two ODM-201 formulations with a safety and tolerability extension phase in patients with metastatic chemotherapy-naive castration-resistant prostate cancer (CRPC)

Journal of clinical oncology, 2014-02, Vol.32 (4_suppl), p.115-115

2014

Volltextzugriff (PDF)

1 – 25 von 43

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(43)
Mit Volltextzugriff
(38)

Publikationsform

Artikel
(43)

Sprache

Englisch
(43)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Humans
(19)
Male
(16)
Life Sciences & Biomedicine
(15)
Science & Technology
(15)
Biological And Medical Sciences
(12)
Adult
(11)
Medical Sciences
(11)
Aged
(7)
Female
(6)
Middle Aged
(6)
Polymorphism
(6)
Receptors, Adrenergic, Alpha-2 - Genetics
(6)
Dexmedetomidine - Pharmacology
(5)
Pharmacology. Drug Treatments
(5)
Prostate Cancer
(5)
Blood Pressure - Drug Effects
(4)
Castration
(4)
Clinical Trials
(4)
Dexmedetomidine
(4)
Echocardiography
(4)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer

Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide

First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours

Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial

Effects of low and high plasma concentrations of dexmedetomidine on myocardial perfusion and cardiac function in healthy male subjects

Prospective-–retrospective biomarker analysis for regulatory consideration: white paper from the industry pharmacogenomics working group

Effects of common polymorphisms in the α1A-, α2B-, β1- and β2-adrenoreceptors on haemodynamic responses to adrenaline

Prediction and impact of attacks of Raynaud's phenomenon, as judged by patient perception

An insertion/deletion polymorphism in the α2b-adrenergic receptor gene is a novel genetic risk factor for acute coronary events

Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial

Acoustic cluster therapy: An overview of research in cancer treatment

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer

Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: An Open-label Phase 1 Study

Abstract 6221: First-in-human study of acoustic cluster therapy consisting of PS101 combined with chemotherapy and insonation in patients with liver metastases of colorectal cancer origin

Impact of darolutamide (DARO) on pain and quality of life (QoL) in patients (Pts) with nonmetastatic castrate-resistant prostate cancer (nmCRPC)

Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC)

The Effects of Sympathectomy on Finger Photoplethysmography and Temperature Measurements in Healthy Subjects

LBA-09 DAROLUTAMIDE DELAYS PROSTATE-SPECIFIC ANTIGEN PROGRESSION AND TIME TO NEXT ANTICANCER THERAPIES IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER

ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC)

ARAMIS trial: Efficacy and safety of ODM-201 in men with high-risk nonmetastatic castration-resistant prostate cancer

ARAMIS trial: Efficacy and safety phase 3 trial of ODM-201 in men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC)

A double-blind, randomized, placebo-controlled crossover trial of the α2C-adrenoceptor antagonist ORM-12741 for prevention of cold-induced vasospasm in patients with systemic sclerosis

ODM-201 and the CNS: A clinical perspective

Variation in the alpha2B-adrenoceptor gene as a risk factor for prehospital fatal myocardial infarction and sudden cardiac death

A study of two ODM-201 formulations with a safety and tolerability extension phase in patients with metastatic chemotherapy-naive castration-resistant prostate cancer (CRPC)

Suchergebnisse filtern